190 related articles for article (PubMed ID: 19223741)
1. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.
Wang S; Yang H; Tong F; Zhang J; Yang D; Liu H; Cao Y; Liu P; Zhou P; Cheng L; Liu M; Guo J
Gan To Kagaku Ryoho; 2009 Feb; 36(2):255-8. PubMed ID: 19223741
[TBL] [Abstract][Full Text] [Related]
2. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
Kennedy CR; Gao F; Margenthaler JA
J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
[TBL] [Abstract][Full Text] [Related]
5. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
6. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
8. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
9. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
10. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
11. [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].
Masuda N; Yasojima H; Mizutani M; Yamamura J
Gan To Kagaku Ryoho; 2012 Apr; 39(4):512-8. PubMed ID: 22504674
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
[TBL] [Abstract][Full Text] [Related]
17. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
18. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Liedtke C; Mazouni C; Hess KR; André F; Tordai A; Mejia JA; Symmans WF; Gonzalez-Angulo AM; Hennessy B; Green M; Cristofanilli M; Hortobagyi GN; Pusztai L
J Clin Oncol; 2008 Mar; 26(8):1275-81. PubMed ID: 18250347
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]